VOYXACT is the first and only FDA approved treatment that selectively blocks APRIL.
APRIL (A PRoliferation-Inducing Ligand) is an immune messenger that helps your body make certain types of antibodies to protect you from infections.
However, in IgA nephropathy, APRIL has been linked to the production of abnormal antibodies, including Gd-IgA1.
Over time, these abnormal IgA antibodies can build up in your kidneys, and lead to symptoms like proteinuria.
Blocking APRIL is one way to target the immune system activity of IgA nephropathy—as stated by the KDIGO guidelines.
Blocking APRIL is one way to target the immune system activity of IgA nephropathy—as stated by the KDIGO guidelines.
FDA=U.S. Food and Drug Administration.
IgA=immunoglobulin A.
IgAN=IgA nephropathy.
Gd-IgA1=galactose-deficient IgA1.
KDIGO=Kidney Disease: Improving Global Outcomes.
VOYXACT binds to APRIL.
Blocking APRIL has been shown to reduce the production of abnormal IgA antibodies (Gd-IgA1). These abnormal antibodies play a role in driving IgA nephropathy.
How VOYXACT can fit into your care plan.
Your care plan is unique to you. It’s important to know how VOYXACT can fit into it.
Be sure to continue working with your nephrologist while on VOYXACT. Always reach out to your care team if you have any questions.
VOYXACT is not a steroid;
it is a monoclonal
antibody (biologic).
VOYXACT can be taken
with ACE inhibitors, ARBs,
and/or SGLT2 inhibitors.
VOYXACT does not require
enrollment in an FDA REMS
monitoring program.
ACE inhibitors=angiotensin-converting enzyme inhibitors.
ARBs=angiotensin receptor blockers.
SGLT2 inhibitors=sodium-glucose cotransporter 2 inhibitors.
FDA=U.S. Food and Drug Administration.
REMS=Risk Evaluation and Mitigation Strategies.
